Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07132333) titled 'Molecular Inflammation Board at the Center for Personalized Medicine' on Aug. 11.
Study Type: Observational [Patient Registry]
Primary Sponsor: University Hospital Tuebingen
Condition:
Psoriasis (PsO)
Psoriasis Arthritis
Inflammatory Bowel Disease (Crohn'
s Disease and Ulcerative Colitis)
Spondylarthropathies
Intervention:
Biological: Biologic Agent
Recruitment Status: Recruiting
Date of First Enrollment: November 16, 2022
Target Sample Size: 3000
Countries of Recruitment:
Germany
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07132333
Published by HT Digital Content Services with permissi...